E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer

Clin Breast Cancer. 2003 Feb;3(6):421-2. doi: 10.3816/CBC.2003.n.007.
No abstract available

MeSH terms

  • Antibiotics, Antineoplastic / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Bevacizumab
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Clinical Trials, Phase III as Topic
  • Endothelial Growth Factors / immunology*
  • Female
  • Humans
  • Intercellular Signaling Peptides and Proteins / immunology*
  • Lymphokines / immunology*
  • Neoplasm Metastasis
  • Paclitaxel / therapeutic use*
  • Patient Selection
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors

Substances

  • Antibiotics, Antineoplastic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Phytogenic
  • Endothelial Growth Factors
  • Intercellular Signaling Peptides and Proteins
  • Lymphokines
  • Vascular Endothelial Growth Factor A
  • Vascular Endothelial Growth Factors
  • Bevacizumab
  • Paclitaxel